| Market Capitalization (Millions $) |
5,020 |
| Shares
Outstanding (Millions) |
96 |
| Employees |
201 |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
-569 |
| Cash Flow (TTM) (Millions $) |
185 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
CRISPR Therapeutics AG is a biotechnology company that focuses on developing novel therapies using CRISPR gene-editing technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows precise modifications of genetic material.
The company aims to develop transformative gene-based medicines for serious diseases by utilizing the power of CRISPR. It has a diversified pipeline of potential gene therapies that target a range of genetic disorders, including blood disorders, oncology, regenerative medicine, and rare diseases.
CRISPR Therapeutics AG collaborates with leading academic institutions and pharmaceutical companies to advance its research and development efforts. The company has also established strategic partnerships to support the commercialization and global distribution of its potential therapies.
The company's scientific expertise and cutting-edge technology have garnered significant attention in the biotechnology industry and have the potential to revolutionize the treatment of genetic diseases. As a pioneer in the field of CRISPR gene editing, CRISPR Therapeutics AG continues to push the boundaries of modern medicine and holds great promise for improving patient outcomes.
Company Address: Baarerstrasse 14 Zug 6300
Company Phone Number: 561 32 77 Stock Exchange / Ticker: NASDAQ CRSP
|
4.77% 
68.59 %